menu search

Inhibikase therapeutics highlights unblinded functional analysis from the 201 trial of risvodetinib in untreated parkinson’s disease and provides update on ongoing enrollment

BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceu...

October 16, 2023, 11:00 am

Cogent biosciences presents preclinical data highlighting precision oncology pipeline at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resis...

October 14, 2023, 4:30 pm

Revolution medicines presents encouraging clinical data for rmc-6236 and rmc-6291 at 2023 triple meeting

Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-t...

October 13, 2023, 3:50 pm

Ardelyx to present data updates for xphozah (tenapanor) for hyperphosphatemia at kidney week 2023 november 1-5 in philadelphia, pa

WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develo...

October 13, 2023, 8:00 am

Olema oncology kat6 inhibitor compounds demonstrate potent anti-tumor activity

Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SAN FRANCISCO, Oct. ...

October 12, 2023, 11:01 am

Neurona therapeutics announces publication in cell stem cell reporting the development of investigational novel regenerative cell therapy strategy for drug-resistant focal epilepsy

Publication demonstrates robust and reproducible generation of pure pallial, medial ganglionic eminence (MGE)-type GABAergic inhi...

October 5, 2023, 3:00 pm

Artios to present initial phase 1 clinical monotherapy data for atr inhibitor art0380 in advanced solid tumors at the european society of medical oncology congress 2023

ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in...

October 5, 2023, 12:00 pm

Revolution medicines to present new clinical data at major oncology conferences and host investor webcast

Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhi...

October 4, 2023, 8:05 pm

Kura oncology announces three presentations at aacr-nci-eortc international conference on molecular targets and cancer therapeutics

– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhi...

October 4, 2023, 11:30 am

Foghorn therapeutics to present clinical and pre-clinical data from multiple programs across its diverse pipeline at aacr-nci-eortc international conference

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a ne...

October 4, 2023, 8:00 am

Fusion inhibitors market revenue to cross usd 7.2 billion by 2031, exhibiting a 14.2% cagr: tmr report

Fusion inhibitors play a pivotal role in advanced HIV therapies, enhancing treatment effectiveness and ...

October 4, 2023, 7:52 am

Aligos therapeutics announces award of an $8.5 million niaid contract to advance development of best-in-class pan-coronavirus protease inhibitor, alg-097558

– NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies – This is the second...

October 3, 2023, 11:30 am

Verona pharma to present additional analyses of positive phase 3 enhance studies in copd at chest 2023

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine,  an investigational, novel, se...

October 3, 2023, 2:00 am

Ether futures etfs hit the market as sec mulls next steps on bitcoin fund

Bitcoin futures ETFs already exist, led by the ProShares Bitcoin Strategy ETF (bito), which holds about...

October 2, 2023, 4:44 pm

Genentech to present new key clinical and real-world data at ectrims-actrims 2023 showcasing strength of long-term outcomes in ms and nmosd

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new data for Ocrevus®...

October 2, 2023, 1:00 am

Roche to present new key clinical and real-world data at ectrims-actrims 2023 showcasing strength of long-term outcomes in ms and nmosd

Basel, 02 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data for OCREVUS® (ocrelizumab) and investigational Bruton's tyrosine ki...

October 2, 2023, 1:00 am

Theseus pharmaceuticals: picking up the pieces after a lead failure

Theseus Pharmaceuticals experienced significant losses after discontinuing its lead program, leaving it with a market cap of half of its current asset...

September 29, 2023, 7:35 am

Baudax bio shares rocket as lead clinical candidate gains fda orphan drug designation

Shares of Baudax Bio added 80% after it announced its lead clinical candidate targeting Hemophilia A with inhi...

September 28, 2023, 12:27 pm

Sagimet biosciences: recent ipo with emerging positive data in nash

Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolis...

September 27, 2023, 2:48 pm

Zyversa therapeutics’ ceo, stephen c. glover to participate in panel at the bioflorida conference discussing inflammation and its impact on numerous diseases

Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment. ZyVersa is advancing...

September 27, 2023, 11:07 am


Search within

Pages Search Results: